The Association of periOperative Registered Nurses (AORN) has announced its annual updated recommendations on the “Guideline for Preoperative Patient Skin Antisepsis,” to assist health care professionals in navigating risk-based decisions for developing preoperative decolonization programs. The updated guidelines were developed by an interdisciplinary panel of clinical experts. PDI Healthcare’s Profend Nasal Decolonization Kit is a Povidone-Iodine (PVP-I) antiseptic product specifically designed to be used in the nose. In accordance with the new guideline, Profend swabsticks proactively defend surgical from infections related to Staphylococcus aureus (S. aureus) or Methicillin Resistant Staphylococcus aureus (MRSA).
To help reduce this risk, PVP-I provides a broad-spectrum antiseptic that has been proven effective in reducing both S. aureus and MRSA with no known bacterial resistance, an added advantage over the widely used nasal antibiotic, mupirocin. Profend swabsticks are pre-saturated with 10% w/w PVP-I that can be used for nasal decolonization of almost all patients. The Profend Nasal Decolonization Kits come in sets of four swabs applied for just fifteen seconds each for a total application time of 60 seconds. When administered by a clinician in compliance with manufacturer’s instructions, this procedure kills 99.7% of S. aureus at 10 minutes and 99.9% at 12 hours.[1]
In addition, the CDC guideline, Strategies to Prevent Hospital-onset Staphylococcus aureus Bloodstream Infections in Acute Care Facilities[2], recommends nasal decolonization as a core strategy to reduce S. aureus in high-risk surgeries and high risk patients such as patients in an intensive care unit or those with central venous catheters in place. Up to 30% of adults are nasally colonized with S. aureus or MRSA,3 which can increase the risk of developing an SSI two to nine times.[3,4]
“Surgical site infections remain the most common healthcare-associated infection in the United States, which represents a significant cause of morbidity and mortality,” said Caitlin Stowe, MPH, CPH, CPHQ, CIC, VA-BC, Clinical Research Manager, at PDI Healthcare. “Decolonization protocols utilized in SSI prevention programs, including preoperative nasal PVP-I decolonization, can significantly improve patient outcomes.”
Healthcare facilities have already seen the value of PDI’s Profend nasal decolonization product. New Jersey-based Hunterdon Medical Center uses the product to prevent infections as a part of their patients’ pre-surgical protocols. This has made a difference in how they are preventing SSIs and improving patient outcomes.
In one study conducted by PDI, more than 90% of healthcare providers surveyed preferred Profend Nasal Decolonization Kits over other PVP-I products because the application time is up to 2.5 times faster.[5] To highlight patient preference, a study conducted by Maslow and colleagues found that 96.6% of patients surveyed reported a more comfortable experience with a PVP-I nasal decolonization product versus mupirocin.[6]
PDI has partnered with AORN for an educational webinar, “Nasal Decolonization: Who Nose the New Guidelines Best?” as part of AORN’s Hot Topic Virtual Forum series. PDI Clinical Science Liaisons Deva Rea, MPH, BSN, RN, CIC, and Marc-Oliver Wright, MT (ASCP), MS, CIC, FAPIC will host a webinar on Thursday, June 17 to discuss nasal decolonization recommendations in the new Preoperative Patient Skin Antisepsis Guideline. Participation is free, but space is limited. Interested participants can register here.
EDITOR’S NOTE: The headline for this news post has been updated to avoid any confusion. AORN does not endorse products. Also, please note that the Maslow study mentioned was conducted with a 5% PVP-I nasal antisepsis solution.
REFERENCES
[1]PDI in vivo Study 0113-CTEV
[2] Centers for Disease Control and Prevention. Strategies to Prevent Hospital-onset Staphylococcus aureus Bloodstream Infections in Acute Care Facilities. https://www.cdc.gov/hai/prevent/staph-prevention-strategies.html. Published December 2019.
[3] VandenBergh MF, Yzerman EP, van Belkum A, Boelens HA, Sijmons M, Verbrugh HA. Follow-up of Staphylococcus aureus nasal carriage after 8 years: redefining the persistent carrier state. J Clin Microbiol. 1999;37:3133–3140
[4] Kalmeijer MD, van Nieuwland-Bollen E, Bogaers-Hofman D, de Baere GA. Nasal carriage of Staphylococcus aureus is a major risk factor for surgical-site infections in orthopedic surgery. Infect Control Hosp Epidemiology. 2000;21(15)319-323
[5] PDI user acceptance study
[6] Maslow J, Hutzler L, Cuff G, Rosenberg A, Phillips M, Bosco J. Patient experience with mupirocin or povidone-iodine nasal decolonization. Orthopedics. 2014;37(6):e576–e581.
